This subset is also referred to as luminal A. However, some ER+ breast cancers have a higher risk for recurrence and poorer prognosis, especially in younger women and benefit more from adjuvant chemotherapy [24,25,26]. This evidence concerns the gene ESR1 and breast carcinoma.